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Objectives The aim of this study was to determine the incidence and clinical characteristics of sudden cardiac death (SCD)
in patients with human immunodeficiency virus (HIV) infection.
Background As the HIV-infected population ages, cardiovascular disease prevalence and mortality are increasing, but the inci-
dence and features of SCD have not yet been described.
Methods The records of 2,860 consecutive patients in a public HIV clinic in San Francisco between April 2000 and August
2009 were examined. Identification of deaths, causes of death, and clinical characteristics were obtained by
search of the National Death Index and/or clinic records. SCDs were determined using published retrospective
criteria: 1) the International Classification of Diseases-10th Revision, code for all cardiac causes of death; and
(2) circumstances of death meeting World Health Organization criteria.
Results Of 230 deaths over a median of 3.7 years of follow-up, 30 (13%) met SCD criteria, 131 (57%) were due to ac-
quired immune deficiency syndrome (AIDS), 25 (11%) were due to other (natural) diseases, and 44 (19%) were
due to overdoses, suicides, or unknown causes. SCDs accounted for 86% of all cardiac deaths (30 of 35). The
mean SCD rate was 2.6 per 1,000 person-years (95% confidence interval: 1.8 to 3.8), 4.5-fold higher than ex-
pected. SCDs occurred in older patients than did AIDS deaths (mean 49.0 vs. 44.9 years, p  0.02). Compared
with AIDS and natural deaths combined, SCDs had a higher prevalence of prior myocardial infarction (17% vs.
1%, p  0.0005), cardiomyopathy (23% vs. 3%, p  0.0005), heart failure (30% vs. 9%, p  0.004), and ar-
rhythmias (20% vs. 3%, p  0.003).
Conclusions SCDs account for most cardiac and many non-AIDS natural deaths in HIV-infected patients. Further investiga-
tion is needed to ascertain underlying mechanisms, which may include inflammation, antiretroviral therapy
interruption, and concomitant medications. (J Am Coll Cardiol 2012;59:1891–6) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.024A
iAs patients infected with human immunodeficiency virus
(HIV) experience longer life expectancy with antiretroviral
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2012, accepted February 27, 2012.therapy, their rates of cardiovascular disease (CVD) are
increasing. One of the most feared manifestations of CVD
is sudden cardiac death (SCD), responsible for 5% to 15% of
total deaths in the U.S. (1,2). Many SCDs occur in patients
previously undiagnosed with CVD (3), making the identi-
fication of high-risk populations important for screening
and prevention.
Individuals with HIV have higher rates of CVD than
uninfected subjects, likely because of a combination of
traditional risk factors, HIV-related inflammation, and
antiretroviral therapy (4,5). Cardiovascular abnormalities
strongly associated with SCD are prevalent in HIV-infected
patients, including cardiomyopathy (6), pulmonary hyper-
tension (7), and prolonged corrected QT interval (8).
lthough most persons with HIV still die of acquired
mmune deficiency syndrome (AIDS) (9), given the in-
reased prevalence of CVD in this population, SCD is likely
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mortality. Thus, we sought to deter-
mine the incidence, clinical charac-
teristics, and predictors of SCD over
the past decade in a large cohort of
patients receiving care at an urban,
public HIV clinic.
Methods
Study population. We conducted
a single-center, retrospective cohort
study in a public HIV specialty clinic
in San Francisco, California. We
included 2,860 consecutive patients, all 18 years of age with
documented HIV infection, enrolled between April 1, 2000, and
August 31, 2009. The study was approved by the Institutional
Review Board of the University of California, San Francisco.
Identification of deaths and SCDs. Deaths were identi-
fied using the Social Security Death Index and/or clinic
records. Cause of death was obtained through clinical chart
review and search of either the National Death Index Plus
database (through 2008) or direct evaluation of death
certificates from the San Francisco Department of Public
Health (in 2009). Charts were available for all patients who
died and were independently evaluated by 2 reviewers for
cause of death, circumstances of death, and traditional
cardiovascular risk factors. Disagreements were resolved by
consensus with a third reviewer.
SCDs were defined as deaths meeting 2 published crite-
ria: (1) primary International Classification of Diseases-
10th Revision, code for all cardiac causes (1,2) and (2)
circumstances of death meeting World Health Organiza-
tion criteria for SCD (death within 1 h of symptom onset if
witnessed or within 24 h of being observed alive and
symptom free if not witnessed) (10) or unexpected out-of-
hospital death (11). Cardiac International Classification of
Diseases-10th Revision, codes were disease of the heart (I00
to I09, I11, and I20 to I51), congenital heart disease (Q20
to Q24), and ill-defined cause of death (R95 to R99) (2).
Deaths in hospice or due to overdose, violence, suicide,
cancer, or opportunistic infections were excluded. All unex-
pected out-of-hospital deaths classified as SCDs were con-
firmed as not meeting criteria for AIDS death.
For all SCDs, we recorded the following: symptoms
reported during clinic visits (chest pain, dyspnea, syncope,
and palpitations), cardiac medications at last clinic visit, and
the results of all cardiac studies.
Classification of AIDS and other causes of death. AIDS
deaths were defined as deaths meeting at least 2 of 3
published criteria: 1) primary International Classification of
Diseases-10th Revision, code for HIV-disease–related ill-
ness (B20 to B24); 2) circumstances of death involving
HIV-related infection or illness; or 3) most recent CD4
count 50 cells/mm3 (12). Remaining deaths were classi-
Abbreviations
and Acronyms
AIDS  acquired immune
deficiency syndrome
CI  confidence interval
CVD  cardiovascular
disease
HIV  human
immunodeficiency virus
MI  myocardial infarction
SCD  sudden cardiac
deathed as due to trauma, suicide, substance overdose, and otheratural causes (which included non–AIDS-related cancer,
iver disease, sepsis, seizure, renal disease, pulmonary dis-
ase, and diabetes).
scertainment of HIV and cardiovascular disease char-
cteristics. Baseline characteristics were abstracted from
he clinic’s medical record upon enrollment. We recorded
he following variables: age, sex, race, HIV risk factors,
D4 count, and viral load. For all deaths, we searched
edical records for evidence of CVD (International Clas-
ification of Diseases-Ninth Revision, codes for ischemic
eart disease [410 to 414]; disease of the pericardium,
ndocardium, and/or myocardium [420 to 424]; cardiomy-
pathy [425]; conduction disorders and arrhythmias [426
nd 427]; heart failure [428]; and complications of heart
isease [429]) or CVD risk factors (hypertensive disease
401 to 405], disorders of lipid metabolism [272], chronic
idney disease [585], and diabetes mellitus [250]).
tatistical analysis. Differences in prevalent CVD and risk
actors between SCDs versus AIDS and other natural
eaths were assessed using Fisher exact tests and Wilcoxon
ank sum or Kruskal-Wallis tests. We also used Poisson
egression to compare year-specific crude mortality rates and
o estimate expected background SCD rates by age, race,
nd sex, using all previously identified SCDs (n  252) and
he citywide SCD rate (0.373 per 1,000 person-years) in
an Francisco in 2007 (13) and population sizes by age,
ace, and sex (14). The resulting expected background rates
ere then used in combination with follow-up time in the
ntire cohort to calculate the expected numbers of SCDs in
he HIV cohort and the standardized mortality ratio.
esults
f 2,860 cohort patients, 2,478 (87%) were men and 1,515
53%) were Caucasian; among those with known HIV risk
actors (n  2,482), 1,778 (72%) were men who had sex
ith men, 165 (7%) were injection drug users, and 519
21%) had heterosexual risk. At entry, the median age was
9 years (interquartile range: 33 to 45 years), the median
D4 count was 353 cells/mm3 (interquartile range: 175 to
551 cells/mm3; mean 390 cells/mm3), the median log viral
load was 4.1 copies/ml (interquartile range: 2.9 to 4.9
copies/ml; mean 3.9 copies/ml), and 578 subjects (21%) had
undetectable HIV ribonucleic acid (200 copies/ml), indic-
ative of successful antiretroviral therapy.
Of 230 deaths occurring over a median of 3.7 years of
follow-up, 30 (13%; 95% confidence interval [CI]: 9% to
18%) met criteria for SCDs, 131 (57%; 95% CI: 50% to
63%) were due to AIDS, 25 (11%; 95% CI: 7% to 16%)
were due to other natural diseases, and 44 (19%; 95% CI:
14% to 25%) were due to overdose, suicides, or unknown
causes (Fig. 1). SCDs accounted for 30 of 35 (86%; 95% CI:
70% to 95%) of all cardiac deaths. Although SCD did not
increase as a proportion of total deaths, by 2003, SCD was
often the leading cause of non-AIDS natural deaths. Dur-
ing the 10-year period, the mean SCD rate was 2.6 per
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11.4 per 1,000 person-years (95% CI: 9.6 to 13.6) for AIDS
death (Fig. 2).
Three patients with SCD underwent autopsy; causes of
death were myocardial infarction (MI) (n  2) and severe
cardiomyopathy. More than half of patients with SCD had
histories of tobacco, alcohol, or drug use. Five patients
(17%) had family histories of CVD, and 80% had either
known CVD or CVD risk factors. At their final clinic visits,
33% reported chest pain, palpitations, syncope, and/or
dyspnea; 83% were prescribed cardiac medications. Thirteen
(43%) underwent echocardiography: 8 showed moderately
to severely reduced ejection fractions, 7 diastolic dysfunc-
tion, and 3 pulmonary hypertension. Three of 6 patients
who underwent stress testing demonstrated ischemia; cor-
onary angiography in 2 patients demonstrated no significant
stenoses. Of 23 patients with electrocardiograms, 1 had
atrial fibrillation, 8 met criteria for left ventricular hypertro-
phy, 1 had a prolonged corrected QT interval, and 4 showed
evidence of prior MIs.
Compared with those who died of AIDS, patients with
SCD were similar with respect to ethnicity and sex but a
mean of 4.1 years older, with higher CD4 counts (median
312 vs. 87 cells/mm3, p  0.0001) and lower viral loads
median 3.8 vs. 4.8 copies/ml, p  0.009) (Table 1). Of
atients with laboratory studies within 90 days of death, 12
f 15 (80%; 95% CI: 52% to 96%) patients with SCD had
Figure 1 Mortality Rates by Cause and Year
Acquired immune deficiency syndrome (AIDS)  2 of 3 criteria: 1) primary Internat
ciency virus (HIV)–disease related illness; 2) circumstances of death involving HIV
cardiac death (SCD)  primary ICD-10 code for cardiac cause and meeting World
diabetes, and pulmonary, liver, or renal disease. Other  homicide, suicide, traumD4 counts 200 cells/mm3, and 8 of 15 (53%; 95% CI:7% to 79%) had HIV ribonucleic acid 200 copies/ml,
ompared with 36 (55%; 95% CI: 43% to 68%) and 18
28%; 95% CI: 17% to 40%) of 65 AIDS deaths.
Compared with patients who died of AIDS and other
atural causes combined, those with SCD had a higher
revalence of prior MI (17% vs. 1%, p  0.0005), cardio-
yopathy (23% vs. 3%, p  0.0005), heart failure (30% vs.
9%, p  0.004), arrhythmias (20% vs. 3%, p  0.003),
hypertension (67% vs. 27%, p  0.0005), and hyperlipide-
mia (20% vs. 6%, p 0.03) but a similar prevalence of diabetes
mellitus, chronic renal disease, and chronic pulmonary disease
(Table 2).
On the basis of an expected 6.73 SCDs (given San
Francisco’s 2007 SCD rate and population [13]), the
standardized morality ratio for SCD in this population
was 30/6.73  4.46.
Discussion
Although AIDS remained the leading cause of mortality,
SCD was disproportionately represented in this urban
HIV-infected cohort, accounting for 13% of all deaths and
86% of cardiac deaths, at a rate 4.5-fold higher than
expected. Compared with AIDS deaths, SCDs occurred in
older patients with better control of their HIV disease, as
measured by CD4 count and viral load.
In the general population, most SCD is due to coronary
lassification of Diseases-10th Revision (ICD-10), code for human immunodefi-
d infection or illness; and 3) most recent CD4 count 50 cells/mm3. Sudden
Organization criteria. Other natural  non–AIDS-related cancer, sepsis, seizure,
g overdose.ional C
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with HIV presenting with acute coronary syndromes (5),
and prior MI was strongly associated with SCD. This study
also replicates in the HIV population other risk factors
associated with SCD: cardiomyopathy (16), heart failure
(17), arrhythmias (18), hypertension (19), and hyperlipide-
mia (19).
Patients with SCD had modest immunodeficiency, with
similar CD4 counts (median 312 cells/mm3) and viral loads
(median 3.8 log copies/ml) as the full cohort (353 cells/mm3
and 4.1 log copies/ml, respectively), suggesting that patients
are susceptible to SCD even in the setting of mild HIV
disease. This finding is consistent with the Strategies for
Management of Antiretroviral Therapy study, in which
treatment reduced non-AIDS mortality primarily in pa-
Figure 2 SCD and AIDS Mortality Rates by Year
Mean sudden cardiac death (SCD) rate: 2.6 per 1,000 person-years (95% confiden
Mean acquired immune deficiency syndrome (AIDS) rate: 11.4 per 1,000 person-y
Comparison of SCDs With AIDS Deaths and Other Natural DeathsTable 1 Comparison of SCDs With AIDS Deaths and Other Natu
Characteristic
SCDs
(n  30)
AIDS
(n 
Age at death (yrs) 49.0 10.0 44.
Female 2 (7%) 19 (
African American 12 (40%) 40 (
Asian American 1 (3%) 4 (
Caucasian 16 (54%) 69 (
Hispanic 1 (3%) 17 (
Other 0 (0%) 1 (
Most recent CD4 count (cells/mm3) 312 (165–563) 87 (
Most recent HIV RNA (log copies/ml) 3.8 (3.2–4.5) 4.8 (Values are mean  SD, n (%), or median (interquartile range). *For comparison with SCDs.
AIDS  acquired immune deficiency syndrome; HIV  human immunodeficiency virus; RNA  ribonuctients with CD4 counts 350 cells/l (20). However, of
atients with SCD with recent laboratory studies, more
han half had undetectable viral loads, suggesting that even
atients on effective therapy remain at risk.
Although our study did not address the mechanism(s)
nderlying SCD in the setting of HIV, other large cohorts
ay provide insight. In the Data Collection on Adverse
vents of Anti-HIV Drug study, 16 of 36 fatal MIs were
eported as secondary to an “unclassifiable coronary event
such as sudden death)” (4). In the Strategies for Manage-
ent of Antiretroviral Therapy study, levels of interleukin-6
nd D-dimer at entry were strongly associated with CVD
nd unwitnessed deaths, although few such events occurred
21). Chronic HIV-associated inflammation is thought to
nderlie many non-AIDS conditions, including CVD, con-
erval [CI]: 1.8 to 3.8).
5% CI: 9.6 to 13.6).
eaths
hs
) p Value*
Other Natural Deaths
(n  25) p Value*
8 0.02 48.3 9.0 0.79
0.37 6 (24%) 0.12
0.53 8 (32%) 0.65
1 (4%)
13 (52%)
3 (12%)
0 (0%)
6) 0.0001 304 (100–470) 0.75
4) 0.009 4.0 (3.3–4.6) 0.93ce int
ears (9ral D
Deat
131
9 8.
15%)
30%)
3%)
53%)
13%)
1%)
25–26
4.0–5.leic acid; SCD  sudden cardiac death.
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tality and acute MI risk in patients with higher levels of
serum high-sensitivity C-reactive protein (22,23). Future
investigations may help clarify the role of inflammation and
antiretroviral therapy in SCD.
HIV-infected patients also have a higher prevalence of
prolonged corrected QT interval (8), a risk factor for
malignant arrhythmia and cardiovascular mortality in oth-
erwise healthy subjects (24). A transgenic murine model of
HIV infection has demonstrated acquired sodium and
potassium channelopathy (25,26), suggesting that HIV may
also directly affect cardiac depolarization and repolarization,
thereby predisposing infected patients to malignant ventric-
ular arrhythmias.
Study limitations. This study was limited by its retrospec-
tive data collection. We used commonly used criteria for
retrospective ascertainment of SCD (1,11,13), including
requirement for a primary cardiovascular cause on the death
certificate plus circumstances of death meeting World
Health Organization criteria. Furthermore, all unexpected
out-of-hospital deaths meeting criteria for AIDS death
were excluded as SCD. However, the sensitivity and spec-
ificity of World Health Organization classification and
death record ascertainment for SCD are limited for actual
cardiac and arrhythmic causes (1,13). Therefore, although
we cross-checked multiple records, some SCDs may still
have been misclassified. Notably, we classified sudden
deaths in patients with low CD4 counts as SCD that other
studies classified as AIDS related (9) or unknown (12), so
results across methods are not fully comparable. Therefore,
although previous studies may have underestimated SCD
rates, in the absence of definitive data such as rhythm strips
or autopsy results, we may have overestimated them. Un-
fortunately, autopsy confirmation was available for only a
few SCDs, consistent with low autopsy rates in other
population studies of SCD (1,11).
Our assessment of prevalent conditions was limited by
coding practices. Furthermore, clinical charts were insuffi-
cient to accurately ascertain the duration of antiretroviral
Prevalent Comorbidities in SCDsand in AIDS and Other Natural DeathsTable 2 Prevalent Comorbidities in SCDsand in AIDS and Other Natural Deaths
Comorbidity SCDs
AIDS and Other
Natural Deaths p Value
Cardiac arrhythmias* 6 (20%) 5 (3%) 0.003
Cardiomyopathy 7 (23%) 4 (3%) 0.0005
Chronic pulmonary disease 2 (7%) 5 (3%) 0.32
Chronic renal disease 3 (10%) 14 (9%) 0.74
Type 2 diabetes mellitus 7 (23%) 19 (12%) 0.15
Heart failure 9 (30%) 14 (9%) 0.004
Hyperlipidemia 6 (20%) 10 (6%) 0.03
Hypertension 20 (67%) 42 (27%) 0.0005
Prior myocardial infarction 5 (17%) 1 (1%) 0.0005
*Includes atrial fibrillation, ventricular tachycardia, and other unspecified rhythm disorders.
Abbreviations as in Table 1.therapy; thus, we were unable to evaluate potential associ-ations between treatment duration and SCD. Finally, al-
though we adjusted for age, race, and sex, our estimated
standardized mortality ratio for SCD may be biased high,
since patients with prevalent CVD were overrepresented in
this cohort. However, this may also be an important causal
link between HIV and SCD.
Conclusions
We found that SCDs constituted an unexpectedly high
proportion of overall deaths in this urban HIV cohort, with
most cardiac deaths presenting suddenly. SCD occurred at
a rate more than 4 times expected in the general population,
with similar risk factors. Given that cardiac symptoms were
common in victims of SCD, aggressive primary prevention
of CVD should be considered in HIV-infected patients,
especially those with traditional risk factors. Although
implantable cardioverter-defibrillators have been shown to
be life saving in certain clinical settings (16), no studies have
evaluated their utility specifically for patients with HIV. As
we seek to reduce mortality in an aging HIV-infected
population, greater attention must be directed to the mech-
anisms underlying SCD, with the goal of identifying at-risk
patients and ultimately preventing sudden death.
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